Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
OncoResponse, Inc.
OncoResponse, Inc.
Jules Bordet Institute